Patents by Inventor Harold Walder
Harold Walder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220080045Abstract: A method for treating a disease in a subject in need thereof is provided involving infusing 8-methoxypsoralen (8-MOP) and a phosphor-containing drug activator into a diseased site in the subject; and delivering a dose of x-rays to the subject for production of the ultraviolet and visible light inside the subject to activate the photoactivatable drug and induce a persistent therapeutic response, the dose including a pulsed sequence of x-rays delivering from 0.5-2 Gy to the tumor, wherein the phosphor-containing drug activator includes an admixture of two or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays; the two or more phosphors including Zn2SiO4:Mn2+ and (3Ca3(PO4)2Ca(F, Cl)2: Sb3+, Mn2+) at a ratio (Zn2SiO4:Mn2+):(3Ca3(PO4)2Ca(F, Cl)2: Sb3+, Mn2+)) of from 1:10 to 10:1; wherein each of the two or more phosphors have at least one coating selected from an ethyl cellulose coating or a diamond-like carbon coating.Type: ApplicationFiled: November 30, 2021Publication date: March 17, 2022Applicants: IMMUNOLIGHT, LLC, DUKE UNIVERSITYInventors: Harold WALDER, Frederic A. BOURKE, JR., Zakaryae FATHI, Wayne F. BEYER, Mark OLDHAM, Justus ADAMSON, Michael NOLAN
-
Patent number: 11270973Abstract: A polymerizable composition includes at least one monomer, a photoinitiator capable of initiating polymerization of the monomer when exposed to light, and a phosphor capable of producing light when exposed to radiation (typically X-rays). The material is particularly suitable for bonding components at ambient temperature in situations where the bond joint is not accessible to an external light source. An associated method includes: placing a polymerizable adhesive composition, including a photoinitiator and energy converting material, such as a down-converting phosphor, in contact with at least two components to be bonded to form an assembly; and, irradiating the assembly with radiation at a first wavelength, capable of conversion (down-conversion by the phosphor) to a second wavelength capable of activating the photoinitiator, to prepare items such as inkjet cartridges, wafer-to-wafer assemblies, semiconductors, integrated circuits, and the like.Type: GrantFiled: August 17, 2020Date of Patent: March 8, 2022Assignee: Immunolight, LLCInventors: Zakaryae Fathi, James Clayton, Harold Walder, Frederic A. Bourke, Jr.
-
Publication number: 20220062419Abstract: A method and system for treating a subject with a disorder which provides within the subject at least one photoactivatable drug for treatment of the subject, applies initiation energy from at least one source to generate inside the subject a preferential x-ray flux for generation of Cherenkov radiation (CR) light capable of activating at least one photoactivatable drug, and from the CR light, activating inside the subject the at least one photoactivatable drug to thereby treat the disorder.Type: ApplicationFiled: April 12, 2021Publication date: March 3, 2022Applicants: IMMUNOLIGHT, LLC, DUKE UNIVERSITYInventors: Mark OLDHAM, Justus ADAMSON, Mark W. DEWHIRST, Paul YOON, Harold WALDER, Frederic A. Bourke, JR., Zakaryae FATHI, Wayne F. BEYER, JR.
-
Patent number: 11260129Abstract: A phosphor-containing drug activator and suspension thereof are provided. The suspension at least includes two or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays. The two or more phosphors include Zn2SiO4:M12+ and (3Ca3 (PO4)2Ca(F, Cl)2:Sb3*, Mn2+) at a ratio NP-200:GTP-4300 of from 1:10 to 10:1, and each of the two phosphors have an ethylene cellulose coating and/or a diamond-like carbon coating. The suspension further includes a pharmaceutically acceptable carrier.Type: GrantFiled: February 2, 2017Date of Patent: March 1, 2022Assignees: IMMUNOLIGHT, LLC, DUKE UNIVERSITYInventors: Harold Walder, Frederic A. Bourke, Jr., Zakaryae Fathi, Wayne Beyer, Mark Oldham, Justus Adamson, Michael Nolan
-
Patent number: 11207409Abstract: A system (and associated method) for treating a human or animal body. The system has a photoactivatable drug for treating a first diseased site, a first pharmaceutically acceptable carrier including one or more phosphorescent or fluorescent agents which are capable of emitting an activation energy into the body which activates the photoactivatable drug, a first device which infuses the first diseased site with a photoactivatable drug and the first pharmaceutically acceptable carrier, a first energy source which irradiates the diseased site with an initiation energy to thereby initiate emission of the activation energy into the body, and a supplemental treatment device which administers one or both of a therapeutic drug or radiation to the body at a second diseased site or the first diseased site, to provide an immune system stimulation in the body.Type: GrantFiled: May 30, 2018Date of Patent: December 28, 2021Assignees: IMMUNOLIGHT, LLC, DUKE UNIVERSITYInventors: Frederic A. Bourke, Jr., Mark Dewhirst, Neil Spector, Paul Yoon, Justus Adamson, David Alcorta, Kim Lyerly, Leihua Liu, Takuya Osada, Mark Oldham, Zakaryae Fathi, Wayne F. Beyer, Harold Walder
-
Publication number: 20210353954Abstract: A system and method for emitting a wavelength of energy internal to a medium or internal to a human or animal subject, and methods for using the system in the treatment of a condition, disorder, or disease. The system includes 1) a source configured to produce an initiation signal penetrating at least a part of the medium or the human or animal subject and 2) an insertion device having an electronics assembly unit. The assembly unit includes 1) an emitter configured to emit the wavelength of energy of a predetermined type to treat a disease or disorder in the human or animal subject or to produce a change in the medium and 2) a receiver that receives the signal.Type: ApplicationFiled: July 29, 2021Publication date: November 18, 2021Applicant: IMMUNOLIGHT, LLCInventors: Frederic A. BOURKE, JR., Harold WALDER, Zakaryae FATHI, Wayne F. BEYER, JR.
-
Patent number: 11135294Abstract: A method and system for treating a subject with a disorder which provides within the subject at least one photoactivatable drug for treatment of the subject, applies initiation energy from at least one source to generate inside the subject a preferential x-ray flux for generation of Cherenkov radiation (CR) light capable of activating at least one photoactivatable drug, and from the CR light, activating inside the subject the at least one photoactivatable drug to thereby treat the disorder.Type: GrantFiled: October 26, 2016Date of Patent: October 5, 2021Assignees: IMMUNOLIGHT, LLC, DUKE UNIVERSITYInventors: Mark Oldham, Justus Adamson, Mark W. Dewhirst, Paul Yoon, Harold Walder, Frederic A. Bourke, Jr., Zakaryae Fathi, Wayne F. Beyer, Jr.
-
Patent number: 11077316Abstract: A system and method for emitting a wavelength of energy internal to a medium or internal to a human or animal subject, and methods for using the system in the treatment of a condition, disorder, or disease. The system includes 1) a source configured to produce an initiation signal penetrating at least a part of the medium or the human or animal subject and 2) an insertion device having an electronics assembly unit. The assembly unit includes 1) an emitter configured to emit the wavelength of energy of a predetermined type to treat a disease or disorder in the human or animal subject or to produce a change in the medium and 2) a receiver that receives the signal.Type: GrantFiled: April 25, 2017Date of Patent: August 3, 2021Assignee: Immunolight, LLCInventors: Frederic A. Bourke, Jr., Harold Walder, Zakaryae Fathi, Wayne F. Beyer, Jr.
-
Publication number: 20210145028Abstract: A method and a system for producing a change in a medium. The method places in a vicinity of the medium an energy modulation agent. The method applies an initiation energy to the medium. The initiation energy interacts with the energy modulation agent to directly or indirectly produce the change in the medium. The energy modulation agent has a normal predominant emission of radiation in a first wavelength range outside of a second wavelength range (WR2) known to produce the change, but under exposure to the applied initiation energy produces the change. The system includes an initiation energy source configured to apply an initiation energy to the medium to activate the energy modulation agent.Type: ApplicationFiled: December 28, 2020Publication date: May 20, 2021Applicant: IMMUNOLIGHT, LLCInventors: Frederic A. BOURKE, JR., Zakaryae Fathi, Harold Walder, Wayne F. Beyer, JR.
-
Patent number: 10940329Abstract: A phosphor-containing drug activator activatable from a Monte Carlo derived x-ray exposure for treatment of a diseased site. The activator includes an admixture or suspension of one or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays, wherein a distribution of the phosphors in the diseased target site is based on a Monte Carlo derived x-ray dose. A system for treating a disease in a subject in need thereof, includes the drug activator and a photoactivatable drug, one or more devices which infuse the photoactivatable drug and the activator including the pharmaceutically acceptable carrier into a diseased site in the subject; and an x-ray source which is controlled to deliver the Monte Carlo derived x-ray exposure to the subject for production of ultraviolet and visible light inside the subject to activate the photoactivatable drug.Type: GrantFiled: November 21, 2017Date of Patent: March 9, 2021Assignees: IMMUNOLIGHT, LLC, DUKE UNIVERSITYInventors: Mark Oldham, Justus Adamson, Paul Yoon, Harold Walder, Frederic A. Bourke, Jr., Zakaryae Fathi, Wayne F. Beyer
-
Publication number: 20210035946Abstract: A polymerizable composition includes at least one monomer, a photoinitiator capable of initiating polymerization of the monomer when exposed to light, and a phosphor capable of producing light when exposed to radiation (typically X-rays). The material is particularly suitable for bonding components at ambient temperature in situations where the bond joint is not accessible to an external light source. An associated method includes: placing a polymerizable adhesive composition, including a photoinitiator and energy converting material, such as a down-converting phosphor, in contact with at least two components to be bonded to form an assembly; and, irradiating the assembly with radiation at a first wavelength, capable of conversion (down-conversion by the phosphor) to a second wavelength capable of activating the photoinitiator, to prepare items such as inkjet cartridges, wafer-to-wafer assemblies, semiconductors, integrated circuits, and the like.Type: ApplicationFiled: August 17, 2020Publication date: February 4, 2021Applicant: Immunolight, LLCInventors: Zakaryae FATHI, James CLAYTON, Harold WALDER, Frederic A. BOURKE, JR.
-
Patent number: 10874123Abstract: A method and a system for producing a change in a medium. The method places in a vicinity of the medium an energy modulation agent. The method applies an initiation energy to the medium. The initiation energy interacts with the energy modulation agent to directly or indirectly produce the change in the medium. The energy modulation agent has a normal predominant emission of radiation in a first wavelength range outside of a second wavelength range (WR2) known to produce the change, but under exposure to the applied initiation energy produces the change. The system includes an initiation energy source configured to apply an initiation energy to the medium to activate the energy modulation agent.Type: GrantFiled: March 2, 2020Date of Patent: December 29, 2020Assignee: IMMUNOLIGHT, LLCInventors: Frederic A. Bourke, Jr., Zakaryae Fathi, Harold Walder, Wayne F. Beyer, Jr.
-
Publication number: 20200368547Abstract: A method for treating a disease, disorder, or condition in a subject in need thereof, by administering either or both of (i) at least one photoactivatable pharmaceutical agent, or (ii) a first plurality of energy-emitting particles, into the subject in a region of the disease, disorder, or condition, whereby the administering is performed through inhalation; and applying an applied electromagnetic energy to the subject, wherein the applied electromagnetic energy directly or indirectly activates the at least one photoactivatable pharmaceutical agent, when present, and wherein when the first plurality of energy-emitting particles is present, the first plurality of energy-emitting particles absorbs the applied energy and emits an emitted electromagnetic energy, wherein the emitted electromagnetic energy interacts directly with the region of the disease, disorder, or condition or activates the at least one photoactivatable pharmaceutical agent.Type: ApplicationFiled: April 28, 2020Publication date: November 26, 2020Applicants: IMMUNOLIGHT, LLC., DUKE UNIVERSITYInventors: Frederic A. BOURKE, JR., Harold WALDER, Zakaryae FATHI, Michael J. THERIEN, Mark W. DEWHIRST, Ian N. STANTON, Jennifer Ann AYRES, Diane Renee FELS, Joseph A. HERBERT
-
Publication number: 20200365552Abstract: A method of and system for adhesive bonding by a) providing a polymerizable adhesive composition on a surface of an element to be bonded to form an assembly; b) irradiating the assembly with radiation at a first wavelength capable of vulcanization of bonds in the polymerizable adhesive composition by activation of sulfur-containing compound with at least one selected from x-ray, e-beam, visible, or infrared light to thereby generate ultraviolet light in the polymerizable adhesive composition; and c) adhesively joining two or more components together by way of the polymerizable adhesive composition, and a curable polymer for use therein.Type: ApplicationFiled: July 31, 2020Publication date: November 19, 2020Applicant: IMMUNOLIGHT, LLCInventors: Zakaryae FATHI, Frederic A. BOURKE, JR., Harold WALDER
-
Publication number: 20200323711Abstract: A light emitting composition including first color emitters and second color emitters. The first color emitters are configured to emit, upon exposure to an energy source, visible light at a target color in response to absorption of energy across a first band of wavelengths. The second color emitters are configured to emit, upon exposure to the energy source, visible light at the target color in response to absorption of energy across a second band of wavelengths. The light intensity observable at the target color is enhanced relative to reflected white light without emission from the first and second color emitters. The light emitting composition can be a part of a paint, an ink, a fabric, a thread, a road sign, a highway marking, an automobile, a boat, a plane, a reflector, a building product, a concrete product, an epoxy product, a jewelry product, colored contact lens, a candle product, a rubber product, a plastic product, or other colored surface.Type: ApplicationFiled: June 29, 2020Publication date: October 15, 2020Applicant: Immunolight, LLCInventors: Frederic A. BOURKE, JR., Harold WALDER
-
Publication number: 20200282056Abstract: A phosphor-containing drug activator and suspension thereof are provided. The suspension at least includes two or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays. The two or more phosphors include Zn2SiO4:M12+ and (3Ca3 (PO4)2Ca(F, Cl)2:Sb3*, Mn2+) at a ratio NP-200:GTP-4300 of from 1:10 to 10:1, and each of the two phosphors have an ethylene cellulose coating and/or a diamond-like carbon coating. The suspension further includes a pharmaceutically acceptable carrier.Type: ApplicationFiled: February 2, 2017Publication date: September 10, 2020Applicants: IMMUNOLIGHT, LLC, DUKE UNIVERSITYInventors: Harold WALDER, Frederic A. BOURKE, JR., Zakaryae FATHI, Wayne BEYER, Mark OLDHAM, Justus ADAMSON, Michael NOLAN
-
Patent number: 10748868Abstract: A polymerizable composition includes at least one monomer, a photoinitiator capable of initiating polymerization of the monomer when exposed to light, and a phosphor capable of producing light when exposed to radiation (typically X-rays). The material is particularly suitable for bonding components at ambient temperature in situations where the bond joint is not accessible to an external light source. An associated method includes: placing a polymerizable adhesive composition, including a photoinitiator and energy converting material, such as a down-converting phosphor, in contact with at least two components to be bonded to form an assembly; and, irradiating the assembly with radiation at a first wavelength, capable of conversion (down-conversion by the phosphor) to a second wavelength capable of activating the photoinitiator, to prepare items such as inkjet cartridges, wafer-to-wafer assemblies, semiconductors, integrated circuits, and the like.Type: GrantFiled: August 14, 2018Date of Patent: August 18, 2020Assignee: IMMUNOLIGHT, LLCInventors: Zakaryae Fathi, James Clayton, Harold Walder, Frederic A. Bourke, Jr.
-
Patent number: 10734353Abstract: A method of and system for adhesive bonding by a) providing a polymerizable adhesive composition on a surface of an element to be bonded to form an assembly; b) irradiating the assembly with radiation at a first wavelength capable of vulcanization of bonds in the polymerizable adhesive composition by activation of sulfur-containing compound with at least one selected from x-ray, e-beam, visible, or infrared light to thereby generate ultraviolet light in the polymerizable adhesive composition; and c) adhesively joining two or more components together by way of the polymerizable adhesive composition.Type: GrantFiled: July 18, 2019Date of Patent: August 4, 2020Assignee: Immunolight, LLCInventors: Zakaryae Fathi, Frederic A. Bourke, Jr., Harold Walder
-
Publication number: 20200222711Abstract: A system and method for imaging or treating a disease in a human or animal body. The system provides to the human or animal body a pharmaceutical carrier including one or more phosphors which are capable of emitting ultraviolet or visible light into the body and which provide x-ray contrast. The system includes one or more devices which infuse a diseased site with a photoactivatable drug and the pharmaceutical carrier, an initiation energy source comprising an x-ray or high energy source which irradiates the diseased site with at least one of x-rays, gamma rays, or electrons to thereby initiate emission of said ultraviolet or visible light into the body, and a processor programmed to at least one of 1) produce images of the diseased site or 2) control a dose of said x-rays, gamma rays, or electrons to the diseased site for production of said ultraviolet or visible light at the diseased site to activate the photoactivatable drug.Type: ApplicationFiled: December 27, 2019Publication date: July 16, 2020Applicants: IMMUNOLIGHT, LLC., DUKE UNIVERSITYInventors: Harold WALDER, Frederic A. Bourke, JR., Zakaryae Fathi, Wayne F. Beyer, JR., Mark Dewhirst, Mark Oldham, Justus Adamson, Michael Nolan
-
Patent number: 10709900Abstract: A system and method for light stimulation within a medium. The system has a reduced-voltage x-ray source configured to generate x-rays from a peak applied cathode voltage at or below 105 kVp, and a plurality of energy-emitting particles in the medium which, upon radiation from the x-ray source, radiate at a first lower energy than the x-ray source to interact with least one photoactivatable agent in the medium. The method introduces the plurality of energy-emitting particles into the medium, radiates the energy-emitting particles in the medium with x-rays generated from a peak applied cathode voltage at or below 105 kVp; and emits a lower energy than the x-ray source to interact with the medium or with at least one photoactivatable agent in the medium.Type: GrantFiled: January 18, 2019Date of Patent: July 14, 2020Assignees: IMMUNOLIGHT, LLC., DUKE UNIVERSITYInventors: Frederic A. Bourke, Jr., Harold Walder, Zakaryae Fathi, Michael J. Therien, Mark W. Dewhirst, Ian N. Stanton, Jennifer Ann Ayres, Diane Renee Fels, Joseph A. Herbert